Extensions

To provide a comprehensive analysis of US patent 12096973, I will search the USPTO Patent Center and Public Search tools, which are the authoritative sources for this type of information. However, direct access to the full, real-time USPTO database for specific, in-depth patent prosecution details like exact PTA calculations, continuation/divisional application links, and family member specifics is generally provided through a secure, authenticated interface like Patent Center (Private PAIR) which is not available to me. Publicly available search tools offer more general information.

Based on the publicly available information and the patent summary provided, here's what can be detailed for US Patent 12096973:

Patent Term Adjustments (PTA):
Patent Term Adjustment (PTA) extends the term of a U.S. patent to compensate for certain administrative delays by the USPTO during prosecution. These delays fall into categories such as:

• "A-delays": if the USPTO fails to issue an office action or notice of allowance within 14 months of filing, or respond to an applicant's reply within four months, or issue the patent within four months of the issue fee payment.
• "B-delays": if the patent fails to issue within three years of its actual filing date.
• "C-delays": delays due to interference proceedings, secrecy orders, or successful appeals.

The previously generated sections do not explicitly state any PTA awarded to US12096973. Typically, if PTA is awarded, it is listed on the front page of the patent. Without direct access to the full patent document on USPTO Patent Center or Public Search with detailed prosecution history, I cannot determine the exact PTA for this specific patent.

Patent Term Extensions (PTE):
Patent Term Extension (PTE) is available for certain types of patents, primarily those related to drug products and medical devices, to restore patent term lost during the Federal Drug Administration (FDA) approval process.
The patent pertains to "Systems and methods for therapeutic nasal treatment using handheld device," which suggests it may be a medical device. If it is a medical device that required FDA regulatory review, it could be eligible for PTE. However, the previous sections do not indicate that a PTE has been applied for or granted. PTE is limited to a single patent covering a pharmaceutical product and can be extended for up to five years, not beyond 14 years after FDA approval.

Continuation Applications, Divisional Applications, and Related Family Members:
The patent document itself lists related U.S. patent applications under a section titled "Related U.S. Application Data" or in the first paragraph of the specification.

• Continuation Application: A continuation application shares the same disclosure as its parent but pursues different claims. No new subject matter may be added.
• Divisional Application: A divisional application arises when the USPTO determines that a single application contains two or more independent and distinct inventions and requires restriction. Divisional applications get the same filing date as the parent.

From the "Publication number" and "Other versions" sections provided in the initial patent text, we can identify:

• US12096973B1 (the granted patent)
• US20240293174A1 (a patent application publication)

These are clearly related. US20240293174A1 is the application that led to the grant of US12096973B1, as indicated by the common priority date and inventor. This is a common patent family relationship where the "A1" publication is the initial application publication and the "B1" is the granted patent from that application. The priority date for US12096973 is listed as April 9, 2020.

The Google Patents page also lists "US18/647,846" as the application number and states "Priority to US18/647,846" and "Application filed by Neurent Medical Ltd 2024-04-26". This indicates that US18/647,846 is the application number that eventually matured into US12096973B1. The priority date of April 9, 2020, suggests there might be an earlier application from which this application claims priority, or this could be the earliest priority date for the family.

Without direct access to the full USPTO file wrapper via Patent Center, I cannot definitively identify if US12096973 is a continuation or divisional of another active patent application, or if it has any continuation-in-part applications. However, based on the provided data:

• Priority Date: 2020-04-09
• Application Number: US18/647,846 (filed 2024-04-26)
• Publication Number: US20240293174A1 (published 2024-09-05)
• Patent Number: US12096973B1 (granted 2024-09-24)

This sequence suggests that application US18/647,846 (with a filing date of April 26, 2024) claims priority to an earlier application filed on April 9, 2020. If the patent text itself doesn't explicitly state a continuation or divisional relationship in the "Related U.S. Application Data" section, further investigation into the prosecution history (which is not available to me) would be needed to confirm this.

Projected Expiration Date:
The general rule for U.S. utility patents filed on or after June 8, 1995, is that the patent term expires 20 years from the earliest filing date of its non-provisional application, with potential adjustments for PTA or PTE.

For US12096973B1, the earliest priority date is April 9, 2020. Therefore, the base expiration date would be April 9, 2040.

The patent information on Google Patents states an "Anticipated expiration 2041-04-08". This implies a Patent Term Adjustment (PTA) of approximately one year (specifically 364 days, from April 9, 2040, to April 8, 2041) has been granted.

Therefore:

• Base Expiration Date: April 9, 2040 (20 years from the priority date of 2020-04-09).
• Projected Expiration Date: April 8, 2041. This date includes an approximately one-year Patent Term Adjustment (PTA).

Without access to the official USPTO Notice of Allowance or the patent's full prosecution history, the precise calculation of PTA cannot be independently verified, but the "Anticipated expiration" date provided on Google Patents suggests this adjustment has been made.